Zilebesiran - Alnylam Therapeutics
Alternative Names: AGT siRNA - Alnylam Pharmaceuticals; ALN-AGT; ALN-AGT-01; RG-6615Latest Information Update: 16 Jul 2024
At a glance
- Originator Alnylam Pharmaceuticals
- Developer Alnylam Pharmaceuticals; Charite - Universitatsmedizin Berlin
- Class Antihypertensives; Small interfering RNA
- Mechanism of Action Angiotensinogen expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hypertension
- No development reported Preeclampsia
Most Recent Events
- 05 Jun 2024 Phase-I/II clinical trials in Hypertension in Japan (SC) (NCT06423352)
- 21 May 2024 Alnylam Pharmaceuticals plans to initiate a phase I/II trial for Hypertension in June 2024 (SC) (NCT06423352)
- 09 May 2024 Roche plans to file regulatory application for Hypertension in or after 2027 (Roche pipeline, May 2024)